Non-invasive Ventilation and Dex in Critically Ill Adults
Status:
Not yet recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Non-Invasive ventilation (NIV) is a life saving intervention for patients with acute
respiratory failure (ARF). Some patients are not able to tolerate the NIV intervention and
ultimately fail, requiring the use of invasive mechanical ventilation (IMV) and intubation.
Sedation may improve a patient's NIV tolerance. However, this practice has not been adopted
by intensivists as the risk of over-sedation resulting in respiratory depression, inability
to protect the airway, and inadvertent need for intubation are all large deterrents of
sedative use in NIV.
The Non-invasive Ventilation and Dexmedetomidine in Critically Ill Adults: a Vanguard
Pragmatic Randomized Controlled Trial (inDEX) is looking to evaluate the effectiveness of
dexmedetomidine compared to placebo in reducing non-invasive ventilation failures in patients
admitted to the hospital with acute respiratory failure. The results from this pilot trial,
will subsequently inform a large, pragmatic, powered trial to definitively address the
question.